Immunotherapy for advanced renal cell carcinoma (RCC)! The 5-year survival rate of opdivo is 26%, and the curative effect is better than that of Everest!

February 17, 2020 / BIOON / -- BMS recently held ASCO-GU in San Francisco In 2020), the 5-year follow-up results of the phase III checkmate-025 study on the treatment of advanced renal cell carcinoma (RCC) with opdivo (nivolumab) were published Results it was further confirmed that compared with everolimus, opdivo treatment prolonged the overall survival time (OS) and improved the objective response rate (ORR) Checkmate-025 is an open label, randomized phase III study in 803 patients with advanced or metastatic RCC who previously received antiangiogenic drug therapy In the study, patients received 3 mg / kg of opdivo (n = 406) intravenously once every two weeks or 10 mg of everolimus (n = 397) orally once a day until the disease progressed or the unacceptable toxicity The primary endpoints were overall survival (OS), and secondary endpoints included objective response rate (ORR), progression free survival (PFS), quality of life (QOL), and safety According to the data released at the meeting, after a minimum follow-up of 64 months, patients receiving opdivo continued to show OS benefits, with 26% of patients still alive, compared with 18% of patients receiving everolimus In addition, 23% of patients receiving opdivo experienced objective remission, compared with 4% of patients receiving everolimus Median duration of remission (mdor) also continued to be longer in patients treated with opdivo than in patients treated with everolimus (18.2 months vs 14 months) The overall safety is consistent with the previously reported analysis of checkmate-025 During long-term follow-up, there were no new safety signals or drug-related deaths At least 5 years of follow-up, the incidence and type of treatment-related adverse events (AE) were consistent with the preliminary analysis 21% of the patients in the opdivo group had treatment-related grade 3 / 4 AE, compared with 37% in the everolimus group "The 5-year survival rate of checkmate-025 and the sustained response rate observed in the trial highlight the potential for long-term survival and efficacy of opdivo monotherapy in patients with advanced renal cell carcinoma who have previously been treated," said Robert J motzer, MD, chief investigator of the study and director of renal cancer at slonkettling cancer center These data represent the longest follow-up time of PD-1 immunosuppressive checkpoint inhibitors in this case, and emphasize that opdivo can provide a potentially higher survival rate for patients with advanced renal cell carcinoma who have been treated with antiangiogenic drugs " Dr Brian Lamon, head of urinary and reproductive system development at Bristol Myers Squibb, said: "the latest checkmate-025 results support why opdivo monotherapy has become a standard treatment for previously treated renal cell carcinoma patients around the world, and provide more evidence that opdivo treatment may help patients prolong their lives This study represents the exciting progress we have made in improving the survival rate of all patients " Renal cell carcinoma (RCC) is the most common type of renal cancer in adults, causing more than 140000 deaths worldwide every year The incidence rate of RCC in males is 2 times that of women, and the highest incidence rate in North America and Europe Globally, the 5-year survival rate of patients with metastatic or advanced renal cancer was 12.1% Opdivo belongs to PD - (L) 1 tumor immunotherapy, which aims to use the human body's own immune system to resist cancer, and block the PD-1 / PD-L1 signal pathway to make cancer cells die It has the potential to treat various types of tumors So far, opdivo has been approved for a variety of cancer indications Original source: updated checkmate - 025 results show 26% of patients treated with opera are alive at five years in patients with previously treated advanced or metastatic internal cell cardioma